{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:51:47Z","timestamp":1783662707502,"version":"3.55.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010882","name":"Tianjin Municipal Education Commission","doi-asserted-by":"publisher","award":["2023KJ049"],"award-info":[{"award-number":["2023KJ049"]}],"id":[{"id":"10.13039\/501100010882","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010882","name":"Tianjin Municipal Education Commission","doi-asserted-by":"publisher","award":["2023KJ048"],"award-info":[{"award-number":["2023KJ048"]}],"id":[{"id":"10.13039\/501100010882","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010229","name":"Natural Science Foundation of Tianjin Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["22JCZDJC00110"],"award-info":[{"award-number":["22JCZDJC00110"]}],"id":[{"id":"10.13039\/501100010229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82401770"],"award-info":[{"award-number":["82401770"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.schres.2025.03.016","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T19:32:02Z","timestamp":1741807922000},"page":"9-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Prediction of treatment response in drug-na\u00efve schizophrenia patients from the perspective of targeted metabolomics"],"prefix":"10.1016","volume":"278","author":[{"given":"Shuo","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeqing","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.schres.2025.03.016_bb0005","doi-asserted-by":"crossref","first-page":"E314","DOI":"10.1007\/BF02854902","article-title":"Lipids and lipidomics in brain injury and diseases","volume":"8","author":"Adibhatla","year":"2006","journal-title":"AAPS J."},{"issue":"2","key":"10.1016\/j.schres.2025.03.016_bb0010","first-page":"137","article-title":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"9","author":"Anon","year":"2020","journal-title":"The Lancet. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2025.03.016_bb0015","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/jnc.15759","article-title":"Contribution of ceramides metabolism in psychiatric disorders","volume":"164","author":"Bernal-Vega","year":"2023","journal-title":"J. Neurochem."},{"issue":"6","key":"10.1016\/j.schres.2025.03.016_bb0020","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1021\/acschemneuro.3c00678","article-title":"Potential metabolite biomarkers of multiple sclerosis from multiple biofluids","volume":"15","author":"Bhinderwala","year":"2024","journal-title":"ACS Chem. Nerosci."},{"issue":"2","key":"10.1016\/j.schres.2025.03.016_bb0025","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s12640-017-9798-6","article-title":"Ceramide and its related neurochemical networks as targets for some brain disorder therapies","volume":"33","author":"Brodowicz","year":"2018","journal-title":"Neurotox. Res."},{"issue":"4","key":"10.1016\/j.schres.2025.03.016_bb0030","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/schbul\/sbac041","article-title":"Maintenance treatment with antipsychotic drugs in schizophrenia: a Cochrane systematic review and meta-analysis","volume":"48","author":"Ceraso","year":"2022","journal-title":"Schizophr. Bull."},{"issue":"9","key":"10.1016\/j.schres.2025.03.016_bb0035","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1021\/pr1003449","article-title":"Metabolic profiling and the metabolome-wide association study: significance level for biomarker identification","volume":"9","author":"Chadeau-Hyam","year":"2010","journal-title":"J. Proteome Res."},{"issue":"5","key":"10.1016\/j.schres.2025.03.016_bb0040","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/0269881120908016","article-title":"Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: a systematic review and meta-analysis of double-blind randomised controlled trials","volume":"34","author":"Chang","year":"2020","journal-title":"Journal of psychopharmacology (Oxford, England)"},{"key":"10.1016\/j.schres.2025.03.016_bb0045","article-title":"Current state of fluid lipid biomarkers for personalized diagnostics and therapeutics in schizophrenia spectrum disorders and related psychoses: a narrative review","volume":"13","author":"Couttas","year":"2022","journal-title":"Front. Psych."},{"key":"10.1016\/j.schres.2025.03.016_bb0050","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.schres.2017.09.021","article-title":"A systematic review of metabolite biomarkers of schizophrenia","volume":"195","author":"Davison","year":"2018","journal-title":"Schizophr. Res."},{"issue":"12","key":"10.1016\/j.schres.2025.03.016_bb0055","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1177\/00048674241274314","article-title":"Prevalence of treatment-resistant schizophrenia among people with early psychosis and its clinical and demographic correlates","volume":"58","author":"Detanac","year":"2024","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2025.03.016_bb0060","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40263-024-01089-w","article-title":"Sex differences between female and male individuals in antipsychotic efficacy and adverse effects in the treatment of schizophrenia","volume":"38","author":"Galbally","year":"2024","journal-title":"CNS Drugs"},{"issue":"10","key":"10.1016\/j.schres.2025.03.016_bb0065","doi-asserted-by":"crossref","DOI":"10.1172\/JCI165019","article-title":"CERT1 mutations perturb human development by disrupting sphingolipid homeostasis","volume":"133","author":"Gehin","year":"2023","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.schres.2025.03.016_bb0070","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.76","article-title":"Schizophrenia shows a unique metabolomics signature in plasma","volume":"2","author":"He","year":"2012","journal-title":"Transl. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2025.03.016_bb0075","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0920-9964(97)00151-5","article-title":"The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia","volume":"30","author":"Horrobin","year":"1998","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2025.03.016_bb0080","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/schbul\/sbac130","article-title":"Association between human blood metabolome and the risk of psychiatric disorders","volume":"49","author":"Jia","year":"2023","journal-title":"Schizophr. Bull."},{"issue":"9","key":"10.1016\/j.schres.2025.03.016_bb0085","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.37765\/ajmc.2022.89163","article-title":"Burden of EPS in commercial patients with schizophrenia initiating atypical antipsychotics","volume":"28","author":"Kadakia","year":"2022","journal-title":"Am. J. Manag. Care"},{"issue":"2","key":"10.1016\/j.schres.2025.03.016_bb0090","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2025.03.016_bb0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41398-019-0519-1","article-title":"Clozapine-dependent inhibition of EGF\/neuregulin receptor (ErbB) kinases","volume":"9","author":"Kobayashi","year":"2019","journal-title":"Transl. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2025.03.016_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25042294","article-title":"Association of blood metabolomics biomarkers with brain metabolites and patient-reported outcomes as a new approach in individualized diagnosis of schizophrenia","volume":"25","author":"Krzy\u015bciak","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.schres.2025.03.016_bb0105","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s40265-021-01556-4","article-title":"Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations","volume":"81","author":"L\u00e4hteenvuo","year":"2021","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.schres.2025.03.016_bb0110","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00406-018-0971-6","article-title":"Profiling of lipidomics before and after antipsychotic treatment in first-episode psychosis","volume":"270","author":"Leppik","year":"2020","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.schres.2025.03.016_bb0115","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/pcn.13194","article-title":"Alteration of lipids and amino acids in plasma distinguish schizophrenia patients from controls: a targeted metabolomics study","volume":"75","author":"Liu","year":"2021","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.schres.2025.03.016_bb0120","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/17425255.2021.1885648","article-title":"Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia: a systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Marchi","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"7","key":"10.1016\/j.schres.2025.03.016_bb0125","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40263-023-01022-7","article-title":"Increased metabolic potential, efficacy, and safety of emerging treatments in schizophrenia","volume":"37","author":"Meyer","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2025.03.016_bb0130","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.schres.2017.03.031","article-title":"Lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis: a systematic review and meta-analysis","volume":"190","author":"Misiak","year":"2017","journal-title":"Schizophr. Res."},{"issue":"39","key":"10.1016\/j.schres.2025.03.016_bb0135","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.2174\/1381612827666210804110139","article-title":"Metabolomic connections between schizophrenia, antipsychotic drugs and metabolic syndrome: a variety of players","volume":"27","author":"Molina","year":"2021","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.schres.2025.03.016_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2019.109855","article-title":"Global DNA hypomethylation and its correlation to the betaine level in peripheral blood of patients with schizophrenia","volume":"99","author":"Murata","year":"2020","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2025.03.016_bb0145","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/jnr.21822","article-title":"Evidence for disruption of sphingolipid metabolism in schizophrenia","volume":"87","author":"Narayan","year":"2009","journal-title":"J. Neurosci. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2025.03.016_bb0150","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.schres.2015.02.004","article-title":"Proinflammatory cytokines and their membrane-bound receptors are altered in the lymphocytes of schizophrenia patients","volume":"164","author":"Pandey","year":"2015","journal-title":"Schizophr. Res."},{"issue":"W1","key":"10.1016\/j.schres.2025.03.016_bb0155","doi-asserted-by":"crossref","first-page":"W398","DOI":"10.1093\/nar\/gkae253","article-title":"MetaboAnalyst 6.0: towards a unified platform for metabolomics data processing, analysis and interpretation","volume":"52","author":"Pang","year":"2024","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.schres.2025.03.016_bb0160","article-title":"Sarcosine may induce EGF production or inhibit the decline in EGF concentrations in patients with chronic schizophrenia (results of the PULSAR study)","volume":"16","author":"Pawlak","year":"2023","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"10","key":"10.1016\/j.schres.2025.03.016_bb0165","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1177\/0269881119856558","article-title":"Therapeutic potential and underlying mechanism of sarcosine (N-methylglycine) in N-methyl-D-aspartate (NMDA) receptor hypofunction models of schizophrenia","volume":"33","author":"Pei","year":"2019","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"2\u20133","key":"10.1016\/j.schres.2025.03.016_bb0170","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s12035-009-8096-6","article-title":"Deregulated sphingolipid metabolism and membrane organization in neurodegenerative disorders","volume":"41","author":"Piccinini","year":"2010","journal-title":"Mol. Neurobiol."},{"issue":"3","key":"10.1016\/j.schres.2025.03.016_bb0175","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2020.03.008","article-title":"Epigenetic modifications in schizophrenia and related disorders: molecular scars of environmental exposures and source of phenotypic variability","volume":"89","author":"Richetto","year":"2021","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2025.03.016_bb0180","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.biopsych.2004.03.019","article-title":"Altered thalamic membrane phospholipids in schizophrenia: a postmortem study","volume":"56","author":"Schmitt","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2025.03.016_bb0185","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/978-3-319-47656-8_11","article-title":"Lipidomics, biomarkers, and schizophrenia: a current perspective","volume":"965","author":"Sethi","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"issue":"4","key":"10.1016\/j.schres.2025.03.016_bb0190","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/schbul\/sbs058","article-title":"Skin ceramide alterations in first-episode schizophrenia indicate abnormal sphingolipid metabolism","volume":"39","author":"Smesny","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2025.03.016_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115070","article-title":"Potential plasma biomarker panels identification for the diagnosis of first-episode schizophrenia and monitoring antipsychotic monotherapy with the use of metabolomics analyses","volume":"321","author":"Song","year":"2023","journal-title":"Psychiatry Res."},{"issue":"9","key":"10.1016\/j.schres.2025.03.016_bb0200","doi-asserted-by":"crossref","first-page":"818","DOI":"10.30773\/pi.2023.0121","article-title":"Identification of plasma biomarkers in drug-na\u00efve schizophrenia using targeted metabolomics","volume":"20","author":"Su","year":"2023","journal-title":"Psychiatry Investig."},{"key":"10.1016\/j.schres.2025.03.016_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105195","article-title":"Contribution of copy number variants on antipsychotic treatment response in Han Chinese patients with schizophrenia","volume":"105","author":"Sun","year":"2024","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.schres.2025.03.016_bb0210","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/jnnp-2020-323520","article-title":"Fluid biomarkers in frontotemporal dementia: past, present and future","volume":"92","author":"Swift","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2025.03.016_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22063010","article-title":"Applications of metabolomics in forensic toxicology and forensic medicine","volume":"22","author":"Szeremeta","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.schres.2025.03.016_bb0220","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jpsychires.2013.01.016","article-title":"Altered fatty acid concentrations in prefrontal cortex of schizophrenic patients","volume":"47","author":"Taha","year":"2013","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.schres.2025.03.016_bb0225","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.schres.2013.05.028","article-title":"Definition and description of schizophrenia in the DSM-5","volume":"150","author":"Tandon","year":"2013","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2025.03.016_bb0230","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1017\/S1092852918000962","article-title":"Pharmacotherapy of schizophrenia: toward a metabolomic-based approach","volume":"24","author":"Tayeb","year":"2019","journal-title":"CNS Spectr."},{"issue":"1","key":"10.1016\/j.schres.2025.03.016_bb0235","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbab353","article-title":"Comparison of imputation and imputation-free methods for statistical analysis of mass spectrometry data with missing data","volume":"23","author":"Taylor","year":"2022","journal-title":"Brief. Bioinform."},{"issue":"10","key":"10.1016\/j.schres.2025.03.016_bb0240","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.142","article-title":"Membrane lipidomics in schizophrenia patients: a correlational study with clinical and cognitive manifestations","volume":"6","author":"Tessier","year":"2016","journal-title":"Transl. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2025.03.016_bb0245","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1134\/S0006297921060146","article-title":"Monoamine oxidase as a potential biomarker of the efficacy of treatment of mental disorders","volume":"86","author":"Uzbekov","year":"2021","journal-title":"Biochemistry. Biokhimiia"},{"issue":"3","key":"10.1016\/j.schres.2025.03.016_bb0250","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.bbalip.2012.08.016","article-title":"Formation and function of phosphatidylserine and phosphatidylethanolamine in mammalian cells","volume":"1831","author":"Vance","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.schres.2025.03.016_bb0255","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.MS21078COM5","article-title":"The epidemiology and global burden of schizophrenia","volume":"84","author":"Velligan","year":"2023","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2025.03.016_bb0260","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/15622975.2023.2271965","article-title":"The relationship between alterations in plasma metabolites and treatment responses in antipsychotic-na\u00efve female patients with schizophrenia","volume":"25","author":"Wang","year":"2024","journal-title":"The World Journal of Biological Psychiatry: The Official Journal of the World Federation of Societies of Biological Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2025.03.016_bb0265","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.pscychresns.2013.06.011","article-title":"Altered phospholipid metabolism in schizophrenia: a phosphorus 31 nuclear magnetic resonance spectroscopy study","volume":"214","author":"Weber-Fahr","year":"2013","journal-title":"Psychiatry Res. Neuroimaging"},{"issue":"6","key":"10.1016\/j.schres.2025.03.016_bb0270","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11306-018-1375-3","article-title":"Unbiased lipidomic profiling reveals metabolomic changes during the onset and antipsychotics treatment of schizophrenia disease","volume":"14","author":"Yan","year":"2018","journal-title":"Metabolomics: Official journal of the Metabolomic Society"},{"issue":"8","key":"10.1016\/j.schres.2025.03.016_bb0275","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.euroneuro.2011.12.007","article-title":"Characterization of the neuropsychological phenotype of glycine N-methyltransferase\u2212\/\u2212 mice and evaluation of its responses to clozapine and sarcosine treatments","volume":"22","author":"Yang","year":"2012","journal-title":"European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.schres.2025.03.016_bb0280","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1194\/jlr.R300020-JLR200","article-title":"Regulation of ganglioside biosynthesis in the nervous system","volume":"45","author":"Yu","year":"2004","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.schres.2025.03.016_bb0285","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41398-022-01999-7","article-title":"Acid sphingomyelinase\/ceramide system in schizophrenia: implications for therapeutic intervention as a potential novel target","volume":"12","author":"Zhuo","year":"2022","journal-title":"Transl. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996425000799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996425000799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T04:38:32Z","timestamp":1762317512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996425000799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":57,"alternative-id":["S0920996425000799"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2025.03.016","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of treatment response in drug-na\u00efve schizophrenia patients from the perspective of targeted metabolomics","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2025.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}